Mahmoud Alrifai, MD
Cardiovascular Disease · Houston, TXNPI 1922456219
Payments from drug & device makers
Across 91 payments — averaging $98.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$4K
- Abbott$1K
- Heartflow, Inc.$1K
- Siemens Medical Solutions USA, Inc.$1K
- AstraZeneca$395
- Amgen$273
- plus $912 from 11 others
Across 3 payments — averaging $842.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
What the payments were for
- Speaking & faculty fees$2,84532%
- Travel & lodging$2,89332%
- Food & beverage$3,02534%
- Education$1702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 7 | $3,671 |
| Abbott | 14 | $1,363 |
| Heartflow, Inc. | 12 | $1,219 |
| Siemens Medical Solutions USA, Inc. | 8 | $1,099 |
| AstraZeneca | 8 | $395 |
| Amgen | 13 | $273 |
| Pfizer | 6 | $185 |
| Medtronic | 8 | $161 |
| Boston Scientific | 1 | $125 |
| Astellas Pharma US Inc | 2 | $124 |
| Novartis | 5 | $104 |
| Cardiovascular Systems Inc. | 1 | $80 |
| Cardiva Medical, Inc. | 1 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Teleflex LLC | 1 | $31 |
| Tactile Systems Technology Inc | 1 | $19 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flyrcado$3,513
- NAEOTOM Alpha$901
- FFRct$841
- Ensite Cardiac Mapping System$649
- QUADRA ASSURA$177
- Fortify Assura, Ellipse ICD$166
- ROTABLATOR$125
- BRILINTA$125
- FARXIGA$124
- CardioMEMS HF System$117
- VYNDAMAX$101
How this compares
$8,933 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ezetimibe | 13 | $631 |
| Metoprolol Succinate | 31 | $421 |
| Hydralazine Hcl | 14 | $272 |
| Rosuvastatin Calcium | 24 | $206 |
| Atorvastatin Calcium | 20 | $166 |
| Furosemide | 24 | $103 |
| Lisinopril | 18 | $99 |
| Amlodipine Besylate | 22 | $83 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Houston
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.